secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2023-03-24T23:59:59+00:00
Accession:  0001564590-23-004328
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA Biotechnology reports 2022 net loss of $15.7M; cash $10.9M; Phase 2 NSCLC trial underway in Europe
--------------------------------------------------------------------------------

- Net loss $15.7M for 2022 vs $12.6M in 2021; R&D expenses $8.9M (up from $3.5M) due to THIO trial startup.
- Cash $10.9M at Dec 31, 2022 vs $10.6M at Dec 31, 2021; G&A expenses $6.1M (up from $4.3M) including $1.1M ratchet share expense.
- First two patients dosed in Phase 2 THIO-101 trial in Europe for advanced NSCLC; plan to initiate second Phase 2 trial THIO-102.
- Pre-IND meeting with FDA for U.S. expansion; positive feedback on manufacturing and clinical development plan.
- Preclinical data presented at SITC for THIO in hepatocellular carcinoma; new telomere-targeting molecule program advanced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000156459023004328/0001564590-23-004328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000156459023004328/maia-8k_20230324.htm
  HTML page:      https://secwatch.observer/filing/0001564590-23-004328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer